

26. A pharmaceutical composition consisting essentially of about 600 micrograms/day of chromium as synthetic chromic tripicolinate and about 300 micrograms/day of biotin, wherein the amounts of chromic tripicolinate and biotin are selected together to provide a greater than additive effect.

REMARKS

The following comments are made to comply with 37 C.F.R. § 1.173(c). Claims 1-24 are pending in the reissue application. Claims 11 through 24 have been added as set forth above.

In accordance with 35 U.S.C. § 251, which requires that the error upon which a reissue is based be one which causes the patent to be "deemed wholly or partly inoperative or invalid, by reason of the patentee claiming more or less than he had a right to claim in the patent," the Applicant intends to broaden some of the claims of the instant reissue application and narrow others. Specifically, Applicant requests reissue of the above-referenced patent in order to add a claim that does not require both a reduction in hyperglycemia and the stabilization of the serum glucose level in an individual. Additionally, Applicant requests reissue of the above-referenced patent in order to add claims that exclude compositions having other active blood glucose serum ingredients.

No other changes have been made and no new matter is added. Support for the amendment is found throughout the specification in general, and specifically on column 3, lines 7-13 of the issued U.S. Patent No. 5,929,066. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 7/24/01

By: Richard E. Campbell

Richard E. Campbell
Registration No. 34,790
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 235-8550